A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index =27 kg/m^2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease. (NCT06383390)
TRIUMPH
This trial is No longer recruiting
Registration number NCT06383390
Program & service
This trial is being run with the Specialty Medicine service, and as part of the Endocrine & Diabetes program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Professor Anthony Russell, Associate Professor Priya Sumithran
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR